SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SMX (Security Matters) Plc is a holding company, which engages in the provision of authentication solutions. It offers brand protection, authentication, and track and trace technology. The company was founded by Haggai Alon on July 1, 2022 and is headquartered in Dublin, Ireland.

SMX (Security Matters) Plc

SMX (Security Matters) PLC

SMX is trending after securing a $250 million capital commitment that extends its operational runway to 2028, fueling community debate between those anticipating a major short squeeze as the company shifts to revenue generation, and others worried about continued dilution and fundamental value.

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Churchill Capital Corp X - Ordinary Shares - Class A

Churchill Capital Corp X 

With its S-4 registration now effective and the merger vote scheduled for February 12, Churchill Capital Corp X (to become Infleqtion) is gaining significant attention. The community is buzzing about its collaboration with NASA on a quantum gravity sensor mission and new energy sector contracts, widely considering the company undervalued compared to peers given its leading neutral-atom technology and existing revenue streams.

Fiserv, Inc. engages in the provision of financial services technology. It operates through the Merchant and Financial segments. The Merchant segment offers commerce-enabling products and services including merchant acquiring and digital commerce and mobile payment services, and security and fraud protection, stored-value, and pay-by-bank solutions to companies of all sizes. The Financial segment provides products and services such as processing of customer loan and deposit accounts, digital payments, and card transactions to financial institutions and corporate and public sector clients. The company was founded by Leslie M. Muma and George D. Dalton on July 31, 1984 and is headquartered in Milwaukee, WI.

Fiserv, Inc.

Following its recent earnings report, Fiserv is seeing divided community discussion around its perceived deep value and turnaround potential under new leadership, while concerns persist over its debt, shrinking margins, and the broader fintech sector's challenges.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is generating buzz following its latest earnings report, where a substantial 2026 guidance predicting profitability and record membership growth is fueling a bullish narrative. This optimism directly contrasts with a quarterly financial miss that has skeptics questioning the sustainability of its aggressive forward outlook amidst broader healthcare sector uncertainties.

Jumia Technologies AG engages in the provision of logistic services. It operates a pan-African e-commerce platform. It operates through the following geographical segments: West Africa, North Africa, East and South Africa, Europe, United Arab Emirates, and Others. The company was founded by Jeremy Hodara, Sacha Poignonnec, Peter Allerstorfer, Manuel Koser, Tunde Kehinde, and Raphael Afaedor in 2012 and is headquartered in Berlin, Germany.

Jumia Technologies Ag - ADR

Jumia Technologies is trending following its Q4 earnings report which showcased a massive reduction in cash burn and accelerating growth, with the CEO asserting no capital raise is needed to reach profitability. The community is highly bullish on Jumia's trajectory as the "Amazon of Africa" in a rapidly growing market, further fueled by recent positive analyst coverage and high price targets.

Evommune, Inc. is a clinical-stage biotechnology company. It engages in the development of medicines for inflammatory diseases. The company was founded by Luis C. Pena, Eugene Andrew Bauer, and Hans Hofland in 2020 and is headquartered in Palo Alto, CA.

Evommune Inc.

Evommune Inc

Evommune Inc. is seeing significant pre-market momentum following positive top-line data from its Phase 2a trial for EVO301 in moderate-to-severe atopic dermatitis, sparking a polarized community debate between bullish expectations of a short squeeze and warnings of a potential dump at market open.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony (UAMY) is a top trending stock following a new joint venture with Americas Gold and Silver to construct a domestic hydromet processing facility for critical minerals, including antimony. The news, amplified by CEO media appearances, is sparking community excitement about bolstering the U.S. supply chain and the potential for a significant short squeeze in the sector.

Spotify Technology SA engages in the provision of digital music services. It operates through the Premium and Ad-Supported segments. The Premium segment provides subscribers with online and offline streaming access of music and podcasts on computers, tablets, and mobile devices. The Ad-Supported segment offers users with limited on-demand online access of music and unlimited online access of podcasts on computers, tablets, and mobile and smart devices. The company was founded by Daniel Ek and Martin Lorentzon on December 27, 2006 and is headquartered in Luxembourg.

Spotify Technology S.A.

Spotify is rallying after a strong earnings report showcased impressive user and subscriber growth alongside improved profitability and optimistic guidance, prompting analyst upgrades and expectations for higher price targets. The community is actively discussing these strategic gains, even as debate continues around recent subscription price increases and competition in the streaming sector.

Warner Bros. Discovery, Inc. is a premier global media and entertainment company, which engages in the provision of a differentiated portfolio of content, brands, and franchises across television, film, streaming, and gaming. It operates through the following segments: Studios, Networks, Direct-to-Consumer (DTC), and Corporate. The Studios segment includes producing and releasing feature films for initial exhibition in theaters, producing and initial licensing television programs to networks services as well as third parties, distributing films and television programs to various third party, internal television, and streaming services, distribution through the home entertainment market related consumer products, and themed experience licensing and interactive gaming. The Networks segment focuses on domestic and international television networks. The DTC segment is involved in premium pay-television and streaming services. The company was founded on June 17, 1985 and is headquartered in New York, NY.

Warner Bros. Discovery Inc - Ordinary Shares - Class A

Warner Bros Discovery Inc

Warner Bros. Discovery (WBD) is trending as Paramount (PSKY) enhances its $30-per-share offer with additional conditions, drawing community skepticism, while Netflix's (NFLX) proposed acquisition faces intensifying antitrust scrutiny from the Justice Department. This dynamic fuels shareholder debate on whether Netflix will counter or if regulatory hurdles will pave the way for Paramount, maintaining uncertainty in the ongoing bidding war.

S&P Global, Inc. engages in the provision of transparent and independent ratings, benchmarks, analytics, and data to the capital and commodity markets worldwide. It operates through the following segments: Market Intelligence, Ratings, Commodity Insights, Mobility, Indices, and Engineering Solutions. The Market Intelligence segment provides multi-asset-class data and analytics integrated with purpose-built workflow solutions. The Ratings segment is involved in credit ratings, research, and analytics, offering investors and other market participants information, ratings, and benchmarks. The Commodity Insights segment focuses on information and benchmark prices for the commodity and energy markets. The Mobility segment offers solutions serving the full automotive value chain including vehicle manufacturers, automotive suppliers, mobility service providers, retailers, consumers, and finance and insurance companies. The Engineering Solutions segment engages in advanced knowledge discovery technologies, research tools, and software-based engineering decision engines to advance innovation, maximize productivity, improve quality, and reduce risk. The company was founded by James H. McGraw and John A. Hill in 1917 and is headquartered in New York, NY.

S&P Global Inc

S&P Global is experiencing a significant sell-off following a weak earnings outlook that has intensified community concerns about AI disruption to its financial data and research services. The market is sharply repricing the stock, sparking debate among investors over whether this represents an overreaction or a fundamental threat to its long-term business model.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ImmunityBio (NASDAQ:IBRX) Trading 14.5% Higher - Here's What Happened

ImmunityBio (NASDAQ:IBRX) Stock Price Up 14.5% - Should You Buy...

ImmunityBio (NASDAQ:IBRX) Shares Up 7.3% - Still a Buy?

ImmunityBio (NASDAQ:IBRX) Shares Up 7.3% - Should You Buy...

Biotech Stocks To Add to Your Watchlist - February 6th

Danaher, Amicus Therapeutics, Vertex Pharmaceuticals, Moderna, argenex, Medpace, and ImmunityBio are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech...

ImmunityBio (NASDAQ:IBRX) Trading Down 4.1% - What's Next?

ImmunityBio (NASDAQ:IBRX) Stock Price Down 4.1% - Time to Sell...

Rapid Innovation is Reshaping Oncology: Stocks in Focus

Rapid advances in immunotherapy, targeted drugs & artificial intelligence-driven research are reshaping oncology, spotlighting select cancer stocks to watch now.

ImmunityBio (NASDAQ:IBRX) Stock Price Up 3.3% - Should You Buy?

ImmunityBio (NASDAQ:IBRX) Stock Price Up 3.3% - Here's Why...

<ul class="summary-bullets"><li>The study builds on data from an early-stage study which evaluated CD19 CAR-NK cell therapy in combination with the Rituximab without Anktiva.</li><li>Durable complete responses were observed in heavily pretreated patients with iNHL in the study, including Waldenström’s Macroglobulinemia, the company said.</li><li>Last month, Immunitybio said that it recently met with the U.S. FDA to discuss its application for Anktiva plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary tumors.</li></ul><p>Immunitybio Inc. (IBRX) said on Monday that it has launched a mid-stage clinical study in patients with indolent B-cell non-Hodgkin lymphoma (iNHL) with no need for chemotherapy.</p><p>The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.immunitybio.com/news-releases/news-release-details/immunitybio-launches-phase-2-chemotherapy-free-car-nk-cell">said</a> that outpatient study will evaluate ImmunityBio’s novel, off-the-shelf cell therapy CD19 CAR-NK in combination with its other drug Anktiva and Rituximab, and will not require any lymphodepleting chemotherapy unlike conventional CAR-T cell therapies.</p><h2 class="st-heading-2">Why The Trial?</h2><p>The study builds on data from an early-stage study which evaluated CD19 CAR-NK cell therapy in combination with the Rituximab without Anktiva. Durable complete responses were observed in heavily pretreated patients with iNHL in the study, including Waldenström’s Macroglobulinemia, the company said.</p><p>The new mid-stage study is designed to evaluate whether further stimulation of innate and adaptive immune responses may enhance the depth and durability of anti-tumor activity, Immunitybio said, while adding that the company is hopeful for Anktiva potentially augmenting the actions of the cell therapy and Rituximab.</p><p>The study will enroll patients with indolent NHL, including Waldenström’s Macroglobulinemia, who are relapsed or are refractory after at least two prior lines of therapy. Treatment will be provided without chemotherapy.</p><h2 class="st-heading-2">Anktiva Troubles</h2><p>Last month, Immunitybio said that it recently met with the U.S. Food and Drug Administration to discuss its application for Anktiva plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary tumors.</p><p>The company had submitted the application in 2025 but was rejected and is now looking to resubmit it with more information. The company then said that it would submit the additional information within 30 days, and that the added information does not need a new trial.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around IBRX shares remained within the ‘bullish’ territory, while message volume remained at ‘high’ levels.</p><p><a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> has gained about 90% over the past 12 months.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-seemingly-confirms-xai-spacex-merger-talks/cZbgtmrR4kZ">Elon Musk Seemingly Confirms xAI-SpaceX Merger Talks</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, an ImmunityBio company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Immunitybio Initiates Another Cell Therapy Trial With No Chemotherapy Needs

The company said that outpatient study will evaluate ImmunityBio’s novel, off-the-shelf cell therapy CD19 CAR-NK in combination with its other drug Anktiva and Rituximab.

Equity

The company said that outpatient study will evaluate ImmunityBio’s novel, off-the-shelf cell therapy CD19 CAR-NK in combination with its other drug Anktiva and Rituximab.


Top Biotech Stocks To Follow Today - February 1st

Danaher, Vertex Pharmaceuticals, Moderna, Vaxcyte, argenex, VivoSim Labs, and ImmunityBio are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks...

Biotech Stocks To Keep An Eye On - January 31st

ImmunityBio, Inc. (NASDAQ:IBRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) have received an average recommendation of "Moderate Buy" from the six research firms that are currently covering the company, MarketBeat...

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $HOOD earnings on Tuesday?

Stocktwits

Robinhood Markets Inc

Stocktwits Polls

A palpable buzz surrounds extremely low shortable shares and high short interest, leading to strong expectations of a significant short squeeze pushing prices higher.

Traders are celebrating rapid international approvals for Anktiva, notably Saudi Arabia's green light for all tumor types, seen as bypassing perceived FDA bureaucracy.

Enthusiasm is high for Anktiva's potential as a revolutionary treatment for all solid tumors, immune restoration, and addressing lymphopenia.

Intense focus on breaching the $7.50 resistance, with traders eyeing a swift rally to double digits and beyond as key catalysts loom.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.09	--	--	N/A
Q3 '25	-$0.11	-$0.07	34.66%	BEAT
Q2 '25	-$0.11	-$0.10	7.41%	BEAT
Q1 '25	-$0.13	-$0.15	-17.19%	MISSED
Q4 '24	-$0.20	-$0.09	55.00%	BEAT

IBRX
ImmunityBio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest IBRX News

IBRXImmunityBio Inc